메뉴 건너뛰기




Volumn 95, Issue 1, 2010, Pages 222-229

The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

EID: 75149198572     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1630     Document Type: Article
Times cited : (50)

References (35)
  • 2
    • 0034705518 scopus 로고    scopus 로고
    • Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution
    • Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S 2000 Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 275:18664-18669
    • (2000) J Biol Chem , vol.275 , pp. 18664-18669
    • Pantel, J.1    Machinis, K.2    Sobrier, M.L.3    Duquesnoy, P.4    Goossens, M.5    Amselem, S.6
  • 3
    • 3042780191 scopus 로고    scopus 로고
    • A commonpolymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone
    • Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougnères P 2004 A commonpolymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36:720-724
    • (2004) Nat Genet , vol.36 , pp. 720-724
    • Dos Santos, C.1    Essioux, L.2    Teinturier, C.3    Tauber, M.4    Goffin, V.5    Bougnères, P.6
  • 4
    • 0027475477 scopus 로고
    • Expression and binding properties of two isoforms of the human growth hormone receptor
    • Sobrier ML, Duquesnoy P, Duriez B, Amselem S, Goossens M 1993 Expression and binding properties of two isoforms of the human growth hormone receptor. FEBS Lett 319:16-20
    • (1993) FEBS Lett , vol.319 , pp. 16-20
    • Sobrier, M.L.1    Duquesnoy, P.2    Duriez, B.3    Amselem, S.4    Goossens, M.5
  • 5
    • 0027178666 scopus 로고
    • Functional characterization of the alternatively spliced, placental human growth hormone receptor
    • Urbanek M, Russell JE, Cooke NE, Liebhaber SA 1993 Functional characterization of the alternatively spliced, placental human growth hormone receptor. J Biol Chem 268:19025-19032
    • (1993) J Biol Chem , vol.268 , pp. 19025-19032
    • Urbanek, M.1    Russell, J.E.2    Cooke, N.E.3    Liebhaber, S.A.4
  • 6
    • 0025765004 scopus 로고
    • A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor
    • Bass SH, Mulkerrin MG, Wells JA 1991 A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. Proc Natl Acad Sci USA 88:4498-4502
    • (1991) Proc Natl Acad Sci USA , vol.88 , pp. 4498-4502
    • Bass, S.H.1    Mulkerrin, M.G.2    Wells, J.A.3
  • 7
    • 70349904753 scopus 로고    scopus 로고
    • Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: A systematic review and meta-analysis
    • Wassenaar MJ, Dekkers OM, Pereira AM, Wit JM, Smit JW, Biermasz NR, Romijn JA 2009 Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J Clin Endocrinol Metab 94:3721-3730
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 3721-3730
    • Wassenaar, M.J.1    Dekkers, O.M.2    Pereira, A.M.3    Wit, J.M.4    Smit, J.W.5    Biermasz, N.R.6    Romijn, J.A.7
  • 9
    • 0036800303 scopus 로고    scopus 로고
    • Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly
    • Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646
    • (2002) Endocr Rev , vol.23 , pp. 623-646
    • Kopchick, J.J.1    Parkinson, C.2    Stevens, E.C.3    Trainer, P.J.4
  • 10
    • 4544273108 scopus 로고    scopus 로고
    • Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization
    • Maamra M, Kopchick JJ, Strasburger CJ, Ross RJ 2004 Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization. J Clin Endocrinol Metab 89:4532-4537
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 4532-4537
    • Maamra, M.1    Kopchick, J.J.2    Strasburger, C.J.3    Ross, R.J.4
  • 11
    • 0035040522 scopus 로고    scopus 로고
    • Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer
    • Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK 2001 Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86:1716-1723
    • (2001) J Clin Endocrinol Metab , vol.86 , pp. 1716-1723
    • Ross, R.J.1    Leung, K.C.2    Maamra, M.3    Bennett, W.4    Doyle, N.5    Waters, M.J.6    Ho, K.K.7
  • 12
    • 0029989302 scopus 로고    scopus 로고
    • Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization
    • Harding PA, Wang X, Okada S, Chen WY, Wan W, Kopchick JJ 1996 Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization. J Biol Chem 271:6708-6712
    • (1996) J Biol Chem , vol.271 , pp. 6708-6712
    • Harding, P.A.1    Wang, X.2    Okada, S.3    Chen, W.Y.4    Wan, W.5    Kopchick, J.J.6
  • 16
    • 33847700931 scopus 로고    scopus 로고
    • Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study
    • Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ 2007 Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75-82
    • (2007) Eur J Endocrinol , vol.156 , pp. 75-82
    • Schreiber, I.1    Buchfelder, M.2    Droste, M.3    Forssmann, K.4    Mann, K.5    Saller, B.6    Strasburger, C.J.7
  • 17
    • 33645221483 scopus 로고    scopus 로고
    • Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: Effect on IGF-I levels, tumor mass, hypertension and glucose tolerance
    • Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G 2006 Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
    • (2006) Eur J Endocrinol , vol.154 , pp. 467-477
    • Colao, A.1    Pivonello, R.2    Auriemma, R.S.3    De Martino, M.C.4    Bidlingmaier, M.5    Briganti, F.6    Tortora, F.7    Burman, P.8    Kourides, I.A.9    Strasburger, C.J.10    Lombardi, G.11
  • 18
    • 15944375488 scopus 로고    scopus 로고
    • Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly
    • Jehle S, Reyes CM, Sundeen RE, Freda PU 2005 Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab 90:1588-1593
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 1588-1593
    • Jehle, S.1    Reyes, C.M.2    Sundeen, R.E.3    Freda, P.U.4
  • 19
    • 33846040409 scopus 로고    scopus 로고
    • Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant
    • Parkinson C, Burman P, Messig M, Trainer PJ 2007 Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92:190-195
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 190-195
    • Parkinson, C.1    Burman, P.2    Messig, M.3    Trainer, P.J.4
  • 22
    • 38449108652 scopus 로고    scopus 로고
    • Pegvisomant-induced lipohypertrophy: Report of a case with histopathology
    • Marazuela M, Daudén E, Ocón E, Moure D, Nattero L 2007 Pegvisomant-induced lipohypertrophy: report of a case with histopathology. Ann Intern Med 147:741-743
    • (2007) Ann Intern Med , vol.147 , pp. 741-743
    • Marazuela, M.1    Daudén, E.2    Ocón, E.3    Moure, D.4    Nattero, L.5
  • 23
    • 65549102025 scopus 로고    scopus 로고
    • Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome
    • Bernabeu I, Cameselle-Teijeiro J, Casanueva FF, Marazuela M 2009 Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome. Eur J Endocrinol 160:869-872
    • (2009) Eur J Endocrinol , vol.160 , pp. 869-872
    • Bernabeu, I.1    Cameselle-Teijeiro, J.2    Casanueva, F.F.3    Marazuela, M.4
  • 24
    • 32544437508 scopus 로고    scopus 로고
    • The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children
    • Binder G, Baur F, Schweizer R, Ranke MB 2006 The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab 91:659-664
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 659-664
    • Binder, G.1    Baur, F.2    Schweizer, R.3    Ranke, M.B.4
  • 26
    • 34547625580 scopus 로고    scopus 로고
    • Growth hormone (GH) receptor isoform in acromegaly: Lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene
    • Schmid C, Krayenbuehl PA, Bernays RL, Zwimpfer C, Maly FE, Wiesli P 2007 Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. Clin Chem 53:1484-1488
    • (2007) Clin Chem , vol.53 , pp. 1484-1488
    • Schmid, C.1    Krayenbuehl, P.A.2    Bernays, R.L.3    Zwimpfer, C.4    Maly, F.E.5    Wiesli, P.6
  • 31
    • 33845504692 scopus 로고    scopus 로고
    • Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA
    • Audí L, Esteban C, Carrascosa A, Espadero R, Pérez-Arroyo A, Arjona R, Clemente M, Wollmann H, Fryklund L, Parodi LA 2006 Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA. J Clin Endocrinol Metab 91:5038-5043
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 5038-5043
    • Audí, L.1    Esteban, C.2    Carrascosa, A.3    Espadero, R.4    Pérez-Arroyo, A.5    Arjona, R.6    Clemente, M.7    Wollmann, H.8    Fryklund, L.9    Parodi, L.A.10
  • 32
    • 33847279018 scopus 로고    scopus 로고
    • Regulation of growth hormone action by gonadal steroids
    • Meinhardt UJ, Ho KK 2007 Regulation of growth hormone action by gonadal steroids. Endocrinol Metab Clin North Am 36:57-73
    • (2007) Endocrinol Metab Clin North Am , vol.36 , pp. 57-73
    • Meinhardt, U.J.1    Ho, K.K.2
  • 33
    • 11244329010 scopus 로고    scopus 로고
    • Mercado M, Espinosa de los Monteros AL, Sosa E, Cheng S, Mendoza V, Hernández I, Sandoval C, Guinto G, Molina M 2004 Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 62: 293-299
    • Mercado M, Espinosa de los Monteros AL, Sosa E, Cheng S, Mendoza V, Hernández I, Sandoval C, Guinto G, Molina M 2004 Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 62: 293-299
  • 35
    • 33845541643 scopus 로고    scopus 로고
    • Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults
    • Yuen KC, Dunger DB 2007 Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes Obes Metab 9:11-22
    • (2007) Diabetes Obes Metab , vol.9 , pp. 11-22
    • Yuen, K.C.1    Dunger, D.B.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.